Rosenbaum Jay D. lowered its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 17.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,626 shares of the medical research company’s stock after selling 2,000 shares during the quarter. Amgen comprises 3.4% of Rosenbaum Jay D.’s holdings, making the stock its 7th largest holding. Rosenbaum Jay D.’s holdings in Amgen were worth $1,795,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently modified their holdings of the company. FMR LLC boosted its holdings in Amgen by 4.8% in the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after acquiring an additional 2,587,041 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Amgen by 0.9% in the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock worth $8,981,266,000 after acquiring an additional 489,720 shares in the last quarter. BlackRock Inc. boosted its holdings in Amgen by 1.9% in the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after acquiring an additional 909,689 shares in the last quarter. Nordea Investment Management AB boosted its holdings in Amgen by 12.9% in the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after acquiring an additional 806,119 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Amgen by 3.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,968,892 shares of the medical research company’s stock worth $683,562,000 after acquiring an additional 121,202 shares in the last quarter. 78.56% of the stock is currently owned by institutional investors.
Several equities research analysts have weighed in on AMGN shares. Mizuho set a $198.00 price target on Amgen and gave the stock a “buy” rating in a report on Sunday, October 29th. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $199.00 price target for the company in a report on Friday, October 27th. Oppenheimer reissued a “buy” rating and issued a $203.00 price target on shares of Amgen in a report on Friday, October 6th. Cann reaffirmed a “buy” rating and set a $203.00 target price on shares of Amgen in a report on Friday, October 6th. Finally, Goldman Sachs Group downgraded Amgen from a “conviction-buy” rating to a “buy” rating in a report on Friday, December 15th. Fifteen analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $191.60.
In other news, Director Carbonnel Francois De sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total value of $283,070.50. The disclosure for this sale can be found here. Insiders sold 8,575 shares of company stock valued at $1,508,836 over the last 90 days. Company insiders own 0.19% of the company’s stock.
Shares of Amgen, Inc. (NASDAQ:AMGN) traded up $1.45 during mid-day trading on Friday, reaching $187.01. The company had a trading volume of 7,029,903 shares, compared to its average volume of 2,880,000. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. The stock has a market capitalization of $136,810.00, a PE ratio of 72.48, a P/E/G ratio of 2.73 and a beta of 1.42. Amgen, Inc. has a 52 week low of $152.16 and a 52 week high of $201.23.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the consensus estimate of $3.03 by ($0.14). The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 29.33%. The firm’s revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.89 earnings per share. research analysts anticipate that Amgen, Inc. will post 12.65 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be given a $1.32 dividend. The ex-dividend date is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.82%. Amgen’s payout ratio is 178.29%.
Amgen announced that its board has approved a share buyback plan on Wednesday, October 25th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.
ILLEGAL ACTIVITY WARNING: “Amgen, Inc. (NASDAQ:AMGN) Position Lowered by Rosenbaum Jay D.” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/03/rosenbaum-jay-d-cuts-holdings-in-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.